
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is viewed favorably because its differentiated light adjustable lens technology is proving resilient, with the ALC collaboration highlighting the value of its platform and management seeing encouraging utilization trends in accounts using its commercial strategy. In 1Q26, revenue beat consensus at $30.9M, LAL revenue was $27.0M with 27,472 units sold and flat Y/Y growth, and gross margin improved to 76.1% on product mix, suggesting strong premium-category positioning despite softer LDD placements. The outlook also benefits from expectations that growth can return in 2H26 as utilization recovers and cash burn improves as LALs become a larger share of total revenue, while management reaffirmed 2026 revenue guidance of $120M-$135M.
Bears say
RxSight is facing fundamental pressure from weaker-than-expected 2Q26 results, with revenue of $32-34M driven partly by a newly announced Alcon collaboration and only $27M of underlying sales versus $32M consensus. The core business showed softness as it sold 24,917 LALs versus 27,867 expected, placed just 12 LDDs versus 26, and implied utilization of 7.2 versus 8.1, pointing to adoption challenges and competitive trialing. Although management raised gross margin guidance to 73-75% and ended with $209M in cash and investments, it also lowered 2026 underlying revenue guidance to $110-120M, kept operating expenses at the high end of $150-160M, and faces risks from limited adoption, stronger competition, and possible dilution.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares